Finland: These 3 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Finland
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: Finland: These 3 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
Tradename | Ingredient | Estimated Entry Opportunity Date |
---|---|---|
XCOPRI | cenobamate | 2025-04-22 |
VOCABRIA | cabotegravir sodium | 2025-02-21 |
OTREXUP | methotrexate | 2025-01-24 |
>Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: Finland: These 3 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
When can XCOPRI (cenobamate) generic drug versions launch?
Generic name: cenobamate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 22, 2025
Generic Entry Controlled by: Finland Patent C20210018
XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug.
This drug has twenty-six patent family members in twenty countries.
See drug price trends for XCOPRI.
The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2025
Generic Entry Controlled by: Finland Patent C20210017
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can OTREXUP (methotrexate) generic drug versions launch?
Generic name: methotrexate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: January 24, 2025
Generic Entry Controlled by: Finland Patent 1,850,892
OTREXUP is a drug marketed by Otter Pharms. There are fourteen patents protecting this drug.
This drug has thirty-seven patent family members in fourteen countries. There has been litigation on patents covering OTREXUP
See drug price trends for OTREXUP.
The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.